指南与共识免疫规划卫生政策与健康促进

自身免疫性肝炎:布莱顿协作组病例定义及免疫接种安全性数据收集、分析与呈现指南

Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
指南 / 共识 · Vaccine · 2024-02-16

布莱顿协作组将自身免疫性肝炎(AIH)列为优先关注的不良事件,制定病例定义与数据收集分析指南。通过系统综述和专家共识,基于组织学、血清学、生化检查及排除其他诊断,确定确诊、很可能和可能的诊断确定性等级,并经外部专家和利益相关方评审,以促进免疫接种安全性数据的可比性。

要点

  • AIH被列为优先关注的不良事件,可能见于COVID-19疫苗接种后。
  • 病例定义通过系统综述和专家共识制定,含确诊、很可能和可能三个诊断确定性等级。
  • 病例定义独立于疫苗接种后时间间隔,可用于确定背景发病率,但不用于指导临床病例管理。

核心结论

  • 该报告介绍了布莱顿协作组自身免疫性肝炎(AIH)病例定义,旨在促进免疫接种安全性数据在不同资源环境下的可比性,但该定义不用于指导临床病例管理。

研究设计与样本

  • 由主题专家和布莱顿协作组流程专家组成的工作组,遵循常规布莱顿流程以加速方式制定,包括系统文献综述和专家共识,历时两个月完成。
  • 文件经外部AIH专家及高、中、低收入国家疫苗安全利益相关方参考组同行评审。

主要发现

  • 组织学、血清学、生化检查及排除其他诊断被认定为定义诊断确定性等级(确诊、很可能和可能)所必需。
  • 工作组对疑似AIH的免疫接种后不良事件报告进行独立分类以测试可用性,并据此最终确定病例定义。

关键数值与推荐

  • 诊断确定性等级分为确诊、很可能和可能,基于组织学、血清学、生化检查及排除其他诊断。
  • 病例定义独立于疫苗接种后时间间隔,可用于确定接种疫苗和未接种疫苗对照组的背景发病率。

临床怎么用

  • 该病例定义适用于免疫接种后报告病例的安全性数据收集与分析,也可用于其他产品(包括药物)的安全性研究,但原文明确指出不用于指导临床病例管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This report introduces a Brighton Collaboration (BC) case definition for autoimmune hepatitis (AIH), which has been classified as a priority adverse event of special interest (AESI), as there were possible cases seen following COVID-19 vaccination. The case definition was developed by a group of subject matter and BC process experts to facilitate safety data comparability across pre- and post-licensure clinical trials, as well as pharmacovigilance activities in multiple settings with diverse resources and healthcare access. The usual BC case definition development process was followed in an expedited manner, and took two months to complete, including finalising the manuscript for publication, instead of the usual 1 year development time. It includes a systematic review of the literature and an expert consensus to define levels of diagnostic certainty for AIH, and provides specific guidelines for data collection and analysis. Histology, serological and biochemical tests and exclusion of alternate diagnosis were considered necessary to define the levels of certainty (definitive, probable and possible). AEFI reports of suspected AIH were independently classified by the WG members to test its useability and these classifications were used to finalise the case definition. The document underwent peer review by external AIH experts and a Reference Group of vaccine safety stakeholders in high-, low- and middle-income countries to ensure case definition useability, applicability, and scientific integrity. The expedited process can be replicated for development of other standardised case definitions for priority AESIs for endemics and epidemics. While applicable to cases reported following immunisation, the case definition is independent of lapsed time following vaccination and, as such, can also be used to determine background incidence for vaccinated and unvaccinated control groups in studies of causal association. While use of this case definition is also appropriate for the study of safety of other products including drugs, it is not meant to guide clinical case management.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kochhar S, Assis DN, Mack C, et al. Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine. 2024. PMID: 38368225. doi:10.1016/j.vaccine.2024.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。